Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ebola convalescent plasma
- Development stage
- Preclinical
- Lead developer
- Clinical Research Management
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Ebola convalescent plasma is plasma collected from individuals who have recovered from Ebola virus disease (EVD). This plasma contains polyclonal antibodies specific to Ebola virus, which can provide **passive immunity** by neutralizing the virus when transfused into infected patients. The presumed primary mechanism is the neutralizing activity of immunoglobulins (mainly IgG, along with IgM and IgA) targeting the Ebola virus glycoprotein. The therapy delivers immediate, short-term immune support while the recipient mounts their own immune response. Collection is typically through apheresis and requires ABO blood group compatibility. Ebola convalescent plasma has been prioritized by WHO for clinical trials and considered feasible, acceptable, and safe, but efficacy data remain limited. It is mainly used in outbreaks when no specific antivirals or vaccines are available, and is included in WHO guidelines for managing EVD[1][3][6][7].
- Brand names
- Ebola convalescent plasma
- Other names
- Ebola CPEVD convalescent plasmaEbola virus convalescent plasmaEbola survivor plasma
02
Targets
GPcl (Ebola virus glycoprotein, cleaved form)
Beyond the preview
Go deeper on Ebola convalescent plasma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ebola convalescent plasma.